Actym Therapeutics
Christopher Thanos has extensive work experience in the biotechnology industry. Christopher is currently the President, CEO, and Cofounder of Actym Therapeutics, a biotechnology company focused on developing novel immuno-oncology therapies for cancer treatment. Prior to their role at Actym Therapeutics, Christopher served as a Senior Director and Director at Halozyme Therapeutics, where they were involved in biotherapeutics discovery and the development of new molecular entities. Christopher also held the position of Director of Protein Engineering at Sutro Biopharma. Additionally, Christopher played a crucial role as a Cofounder of Catalyst Biosciences, where they established initial operations, raised venture capital, and contributed to the invention of various therapeutic technologies and products. Christopher has also worked as a National Cancer Institute Postdoctoral Fellow at both UCSF and Sunesis Pharmaceuticals, conducting research on protein hot spots and small molecules bound to proteins.
Christopher Thanos received their Ph.D. in Molecular Biology and Biochemistry from UCLA, completing their studies from 1994 to 1999.
This person is not in any teams
Actym Therapeutics
Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies,STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy.In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.